The rapid progress of various nanotechnology tools is currently being utilized in the management of several fatal illnesses, including cancer. Nanopolymers that encapsulate anti‐cancer medication present a highly encouraging substitute to traditional therapies, primarily because of their specific targeting and accurate functionality, making them suitable for a variety of uses. Poly(2‐hydroxyethyl methacrylate) (pHEMA) is a non‐toxic polymer derived from the monomer HEMA, which is known for its toxicity. It can be combined with various other polymers and is associated with minimal immune response. The objective of the current investigation is to produce smart polymeric nanoparticles that are responsive to changes in pH and temperature, and capable of encapsulating hesperidin. These hesperidin‐loaded poly(2‐Hydroxyethyl methacrylate‐N‐isopropylacrylamide‐Vinyl imidazole) nanoparticles, referred to as HesSNPs, aim to enhance the bioavailability of hesperidin and augment its therapeutic effectiveness in combating prostate cancer. N‐isopropylacrylamide and Vinyl imidazole were employed as monomers sensitive to temperature and pH, respectively. Nanopolymers that were synthesized underwent characterization through dynamic light scattering (DLS) analyses, scanning electron microscopy (SEM), and Fourier transform infrared spectroscopy (FTIR) to analyze particle size and charge, surface morphology, and functional group determinations, respectively. HesSNPs decreased cell viability of DU‐145 cells. Flow cytometry analysis revealed that apoptosis is the main mechanism underlying cell death after HesSNPs treatment.